Benmargendotelceller i utviklingen av akutt myelogen leukemi
- Prosjektnummer
- 911465
- Ansvarlig person
- Kimberley Joanne Hatfield
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Forskerutdanning - postdoc
- Helsekategori
- Cancer
- Forskningsaktivitet
- 2. Aetiology
Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.
Br J Haematol 2014 Jan;164(2):200-11. Epub 2013 okt 23
PMID: 24383842
Preconditioning serum levels of endothelial cell-derived molecules and the risk of posttransplant complications in patients treated with allogeneic stem cell transplantation.
J Transplant 2014;2014():404096. Epub 2014 okt 8
PMID: 25374676
In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells.
Leuk Res Treatment 2014;2014():143479. Epub 2014 jan 8
PMID: 24527217
Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells.
Expert Opin Ther Targets 2014 Nov;18(11):1237-51. Epub 2014 sep 9
PMID: 25200484
Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors.
Expert Opin Investig Drugs 2013 May;22(5):551-63.
PMID: 23586877
Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients.
Cell Prolif 2013 Oct;46(5):554-62.
PMID: 24073609
Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells.
Oncotarget 2013 Jun;4(6):830-43.
PMID: 23919981
Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.
Br J Haematol 2012 Feb;156(4):468-80. Epub 2011 des 13
PMID: 22150087
High-dose etoposide in allogeneic stem cell transplantation.
Cancer Chemother Pharmacol 2012 Dec;70(6):765-82. Epub 2012 okt 6
PMID: 23053272
Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks.
Eur J Haematol 2012 Dec;89(6):478-90. Epub 2012 okt 26
PMID: 23046151
Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia.
Hematology 2011 Nov;16(6):351-6.
PMID: 22183069
Heat shock protein 90 (HSP90) inhibition in acute myeloid leukemia--targeting of disease heterogeneity through direct and indirect antileukemic effects.
Leuk Res 2011 Sep;35(9):1156-8. Epub 2011 jul 30
PMID: 21802728
Antivascular combo therapy: up-and-coming.
Blood 2010 Sep;116(9):1389-90.
PMID: 20813902
Hypoxia increases HIF-1a expression and constitutive cytokine release by primary human acute myeloid leukaemia cells.
Eur Cytokine Netw 2010 Sep;21(3):154-64. Epub 2010 aug 20
PMID: 20729179
The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia.
Curr Med Chem 2010;17(36):4448-61.
PMID: 21062258
STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia.
Expert Rev Hematol. 2015 Feb;8(1):29-41. Epub 2014 Nov 6.
OXYGEN LEVELS INFLUENCE THE CYTOKINE RELEASE PROFILE OF AML CELLS
Abstract 255, ISEH konferanse i Melbourne, Australia, september 2010, Experimental Hematology.
New therapeutic targets in human acute myeloid leukemia
- Disputert:
- mars 2012
- Hovedveileder:
- Øystein Bruserud
- Kimberley Joanne Hatfield Postdoktor
- Øystein Bruserud Leder av forskningsgruppe
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest